Actuate Therapeutics (ACTU): Analyst Consensus at $9.20 With +1,035% Upside Potential
Key Takeaways
- The central target of $9.20 is the arithmetic mean of five verified analyst price targets, ranging widely from $5.00 to $15.00.
- With shares recently trading near $0.81, reaching $9.20 would require upside of roughly 1,035% — a very large move.
- Coverage is unanimous on the buy side, but firms have been cutting targets sharply as the stock has fallen, and the wide $5–$15 range signals major disagreement.
- The strongest supporting factor is the lead drug candidate elraglusib, a GSK-3β inhibitor in Phase 2 development for hard-to-treat cancers.
- The biggest risk is financial: the company has disclosed substantial doubt about its ability to continue as a going concern, with limited cash runway.
Analyst Price Targets: A Closer Look
Actuate Therapeutics, Inc. (ACTU) is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with no approved products and no commercial revenue. It has a small but active sell-side following, and the five current analyst price targets reviewed here produce a wide, top-heavy range.
The individual targets used are: H.C. Wainwright at $15.00 (Buy), Craig-Hallum at $12.00 (Buy), B. Riley Securities at $8.00 (Buy), Rodman & Renshaw at $6.00 (initiated Buy in July 2026), and Lucid Capital at $5.00 (Buy, trimmed from $6.00 in May 2026). The arithmetic mean of these five figures is $9.20, which is the central target used here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The range is unusually wide — $5.00 to $15.00 — reflecting genuine uncertainty about a pre-revenue biotech. Analysts have been revising downward: H.C. Wainwright cut its target from $20 to $15 in April 2026, and B. Riley lowered its view from $20 to $8. Importantly, several of these targets predate the company's disclosure of going-concern risk, so they may not yet reflect the latest liquidity picture. None of these figures should be read as a guarantee, and the mean is not an official published consensus.
Where ACTU Stands Today and the Road to $9.20
Shares of ACTU recently traded around $0.81, near the low end of a 52-week range of roughly $0.60 to $8.49, with a market capitalization of only about $19–24 million. The stock has fallen roughly 88% over the past year, a decline that has far outpaced any downward revision in analyst targets.
To reach $9.20, the stock would need to gain about 1,035%, a very large move by any standard. Even the lowest published target of $5.00 implies more than 500% upside. The path toward such a level would depend almost entirely on clinical and financial catalysts rather than near-term fundamentals, because the company currently generates no product revenue and reports ongoing net losses.
Bull Case: Elraglusib and Clinical Progress
The core bull case rests on elraglusib, a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). The drug is being studied in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma and in earlier-stage programs for pediatric cancers, melanoma, and colorectal cancer. Positive efficacy or safety data, a favorable regulatory interaction, or a partnership or licensing deal could materially re-rate the shares.
Analysts who maintain Buy ratings generally frame ACTU as a high-risk, high-reward binary on clinical success. Successful financing to extend the cash runway would also remove a major overhang and could support the stock forecast.
Key Risks: Liquidity and Going-Concern Concerns
The dominant risk is financial. Actuate has disclosed substantial doubt about its ability to continue as a going concern, reporting only about $4.4 million in cash as of June 30, 2026 — enough to fund operations into September 2026. Without new capital, the company may be unable to advance elraglusib, which would undermine the entire price forecast.
Additional obstacles include the absence of revenue, a small workforce (roughly a dozen employees), the historical failure rate of oncology drug candidates, and the possibility of dilution if financing is raised at depressed share prices. The sharp decline in the shares and the downward drift in analyst price targets both signal that the market is pricing in meaningful risk.
Technical Picture: Deep Downtrend
From a technical standpoint, ACTU is in a deep, long-term downtrend, trading near the bottom of its 52-week range. The $1.00 level now acts as a psychological resistance zone, with prior support areas from earlier in the year sitting far above the current price. There is no meaningful technical basis near current levels that would point toward the $9.20 target; any move of that magnitude would likely require a fundamental catalyst rather than chart momentum.
What to Watch Going Forward
Analyst price targets for biotech names typically reflect a roughly 12-month research horizon, though individual firms may use different assumptions, and none of the targets reviewed here should be treated as a timing forecast. Investors should monitor financing announcements and cash position, the next earnings report (estimated around mid-November 2026), elraglusib trial updates, any partnership or licensing developments, and further analyst target revisions. For a pre-revenue biotech, the liquidity situation is the most time-sensitive variable.
Final Assessment
The central target of $9.20 — the arithmetic mean of five analyst price targets ranging from $5.00 to $15.00 — implies roughly 1,035% upside from a recent price near $0.81. The bull case hinges on clinical progress for elraglusib and on securing financing, while the bear case centers on going-concern risk, limited cash runway, and the absence of revenue. The unusually wide target range and the pattern of downward revisions underscore how uncertain the outcome remains. Whether ACTU can approach $9.20 depends far more on forthcoming financing and trial developments than on current fundamentals, and no outcome is assured.
Using Tickeron’s AI Tools for Biotech Research
In my own work covering volatile names like this, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to track momentum shifts in real time. The platform applies artificial intelligence across thousands of stocks and ETFs, helping surface potential changes in technical behavior and market conditions more efficiently than manual review alone. For a low-priced, high-volatility biotech such as ACTU, these signals can serve as an additional layer of monitoring alongside clinical and financial updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ACTU's RSI Indicator recovers from oversold territory
The RSI Oscillator for ACTU moved out of oversold territory on September 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 21 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 22 of 24 cases where ACTU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on ACTU as a result. In 35 of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ACTU just turned positive on October 02, 2026. Looking at past instances where ACTU's MACD turned positive, the stock continued to rise in 14 of 17 cases over the following month. The odds of a continued upward trend are 82%.
Following a +29.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACTU advanced for three days, in 87 of 96 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
ACTU moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACTU crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACTU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ACTU entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.889) is normal, around the industry mean (26.780). P/E Ratio (6.500) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ACTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement